Dow Jones Newswires | The U.S. Food and Drug Administration is conducting a safety review of
hormone-therapy drugs that are used to treat prostate cancer to see if
the treatments increase the risk of heart attacks, strokes and diabetes.
The drugs, which fall into a class of products known as
gonadotropin-releasing hormone agonists, are sold under brand names that
include Abbott Laboratories’ Lupron, AstraZeneca PLC’s Zoladex and
Sanofi Aventis SA’s Eligard. The products are designed to lower levels
of male hormones, which can shrink prostate tumors and slow the growth
of prostate cancer.
